Key points – The mammalian target of rapamycin (mTOR) pathway is constitutively activated in the TCL cells and is responsible for TCL proliferation. mTORC1 inhibitors (everolimus) have substantial antitumor activity (44% overall response rate) in patients with relapsed TCL.
Home / Resource Library / The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma